Article -> Article Details

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory pulmonary disease that causes obstructed airflow from the lungs. Its symptoms include breathing difficulties, coughing, mucus production, and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions.

The Chronic Obstructive Pulmonary Disease (COPD) market is expected to show substantial growth over the forecast period. As per Market Research Future (MRFR) analysis, the chronic obstructive pulmonary disease (COPD) market was valued at approximately USD 10.7 billion in 2018 and is projected to register 4.2% of CAGR by 2025.

Market Dynamics

The key factor driving the growth of the global market for chronic obstructive pulmonary disease (COPD) market is the growing prevalence of the chronic obstructive pulmonary disease worldwide, which is expected to fuel demand for chronic obstructive pulmonary disease (COPD) drugs. For example, AS per WHO, Global Burden of Disease Study estimates a global prevalence of 251 million cases of COPD in 2016. It is estimated that COPD will become the world's third leading cause of death by 2030.

Additionally, the rising geriatric population and increasing customer understanding of the new and innovative treatment options also complement market growth. Through research and development in this field to develop more innovative COPD treatment solutions may also give numerous opportunities for more market growth. However, restrictive government regulations are expected to impede business growth.

Regionally, the global chronic obstructive pulmonary disease (COPD) market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to capture a substantial share of the global market for chronic obstructive pulmonary disease (COPD) in the forecast period due to the highly advanced healthcare system and growing cases of chronic obstructive pulmonary disease (COPD) in the region

Europe is projected to be second-largest in the global market for chronic obstructive pulmonary disease (COPD) due to its well-developed market.

The Asia Pacific is projected to be the fastest-growing regional market due to the high number of patients suffering from COPD and the increasing prevalence of respiratory diseases.

The market for chronic obstructive pulmonary disease (COPD) in the Middle East and Africa is projected to rise gradually due to the growth of the healthcare infrastructure.

Key Players

Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel) are some of the key players operating in the global chronic obstructive pulmonary disease (COPD) market.

On regional basis, global refurbished medical devices market is segmented into North America, Europe, Asia Pacific and Middle East and Africa. North America commands the largest market for refurbished medical devices. Huge number of patient population, increasing aging population and cost containment issues related to healthcare budgets are the major reason for the growth of refurbished medical devices market in North America. Europe as the second largest market which is driven by increasing awareness about refurbished medical devices and poor reimbursement policies for new medical devices. Economic crises and low product cost has forced the people for adoption of refurbished medical devices. Asia Pacific is the fastest growing region for refurbished medical devices market. High cost of new medical devices and presence of number of low budget hospitals has led to increase this market in Asia Pacific region.